Percutaneous thermoablation for small renal masses

This study looked at the survival of patients suitable for surgery who underwent percutaneous thermoablation as a first-line treatment for small renal masses (stage T1a). Eighty-five patients who were suitable for surgery were included in the study. These patients had 97 kidney masses that were proven to be malignant (cancerous) with a biopsy (T1a). These […]

read more

CB-839/cabozantinib combination in advanced/metastatic kidney cancer fails to improve progression-free survival

The US Food and Drug Administration (FDA) has granted the drug CB-839 fast track development status when used in combination with cabozantinib for the treatment of patients with metastatic renal cell carcinoma (RCC) who received one or two prior courses of drug treatment (including at least one TKI). Fast track status speeds up the review […]

read more

Nivolumab plus ipilimumab for first-line treatment of advanced kidney cancer: Extended 4-year follow-up

Four-year follow up data are now available from the CheckMate 214 clinical trial with the nivolumab plus ipilimumab combination in patients with metastatic renal cell carcinoma (RCC). These data show an improvement in progression-free and overall survival with the nivolumab plus ipilimumab combination compared to sunitinib in the intermediate-/poor-risk patient groups. The durability of the […]

read more

Top stories from 2020 for kidney cancer

Dr Sumanta (Monty) Pal, Clinical Professor and Co-Director of the Kidney Cancer Programme, at the City of Hope Hospital, California talks about the changes in the management of renal cell carcinoma (RCC) over the past decade. He talks about combination treatments such as nivolumab with ipilimumab, which shows the potential for a complete response in […]

read more

AstraZeneca/Oxford University’s COVID-19 vaccine UK rollout

AstraZeneca and Oxford University’s COVID-19 vaccine is being rolled out in the UK from today, 4 January 2021, following approval by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on 30 December. In a statement released today, the Department of Health and Social Care (DHSC) announced that over half a million doses of the […]

read more

2020 top stories in kidney cancer

This article summarises the key breakthroughs in the treatment of renal cell carcinoma (RCC) in 2020, including a new first-line VEGF-TKI and immunotherapy combination (cabozantinib plus nivolumab) and immunotherapy as a new standard of treatment for patients with non−clear cell RCC and sarcomatoid RCC. Read more in Practice Update here Watch a video interview on […]

read more

Impact of cytoreductive nephrectomy in patients with metastatic kidney cancer

Cytoreductive nephrectomy is the removal of the tumour to reduce the number of cancer cells (tumour burden) and minimise the effects of a potentially immunosuppressive tumour, reduce the symptoms caused by the tumour, and prevent complications. During this study, overall survival was compared between patients with metastatic renal cell carcinoma (RCC) who were treated by […]

read more

Immunotherapy for the treatment of metastatic sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to anti-angiogenic targeted therapy, such as sunitinib and pazopanib. This study […]

read more

IKCS 2020: Treatment selection in kidney cancer

During this interview, Dr Rana McKay from the University of California in San Diego gives a succinct overview of the 19th Annual Meeting of the International Kidney Cancer Symposium (IKCS 2020), including highlights from the meeting. She also discussed the effects of delaying surgery for patients with low stage (T1 and T2) renal cell carcinoma […]

read more

Treatment of kidney masses in patients with VHL disease

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center, Houston, Texas describes how to treat a kidney mass in patients with VHL disease. VHL (von Hippel-Lindau) disease is very rare and affects about 1 in 35,000 people. Between 30 to 70% of people with VHL disease have kidney masses. If the mass […]

read more
Showing 11 to 20 of 966 results
  TOP